Secondary nonresponsiveness to new bulk botulinum toxin A (BCB2024)
We report on a patient with cranio-cervical dystonia injected with the new, lower protein formulation of botulinum toxin A who developed secondary resistance to this toxin. Subsequent injections with botulinum toxin B provided substantial reduction of blepharospasm. This is the first reported case of secondary resistance to the new preparation of botulinum toxin A.
Medical Subject Headings
Blepharospasm (drug therapy); Blinking (drug effects); Botulinum Toxins, Type A (pharmacology, therapeutic use); Female; Humans; Middle Aged; Treatment Outcome
Movement disorders : official journal of the Movement Disorder Society
Digital Object Identifier (DOI)
Racette, Brad A.; Stambuk, Mikula; and Perlmutter, Joel S., "Secondary nonresponsiveness to new bulk botulinum toxin A (BCB2024)" (2002). Neurology. 1177.